Drug Type Small molecule drug |
Synonyms Breelib, Ciloprost, Endoprost + [25] |
Target |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (15 Sep 2003), |
RegulationPriority Review (US), Orphan Drug (US) |
Molecular FormulaC22H32O4 |
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N |
CAS Registry78919-13-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chilblains | US | 14 Feb 2024 | |
Frostbite | US | 13 Feb 2024 | |
Pulmonary Arterial Hypertension | US | 29 Dec 2004 | |
Familial Primary Pulmonary Hypertension | EU | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | IS | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | LI | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | NO | 15 Sep 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CREST Syndrome | Phase 3 | US | 14 Oct 2019 | |
Scleroderma, Systemic | Phase 3 | US | 14 Oct 2019 | |
Hypertension, Pulmonary | Phase 3 | BE | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | FR | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | IT | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | NL | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | PL | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | PT | 01 Feb 2000 | |
Hypertension, Pulmonary | Phase 3 | ES | 01 Feb 2000 | |
Raynaud Disease | Phase 2 | US | 04 Mar 2019 |
Phase 4 | 27 | afbughyxis(adhizgcqxg) = qlfuzsmhdn cmynegfumg (aqhdatcsnn, hrvhrfsryl - nzawayzpgz) View more | - | 02 Apr 2024 | |||
FDA Manual | Not Applicable | 47 | (Groups A) | rpjtklybzi(vldlfujkaf) = ugnzkjbbmb pqgdztsjll (xmdpxyqdki ) | Positive | 13 Feb 2024 | |
(Groups B) | rpjtklybzi(vldlfujkaf) = wurpisatks pqgdztsjll (xmdpxyqdki ) | ||||||
Not Applicable | 50 | Iloprost infusion | izdbrxxcxd(vzbgtwfygy) = mnlkedrrov fsuduuqpxb (bkkntdncct ) View more | Positive | 01 Jun 2022 | ||
Not Applicable | 31 | zlkugavlgb(xhkykgylbl) = btursawqdj trcqltrzuj (kzxzbrrlwn ) View more | - | 08 Oct 2021 | |||
Not Applicable | Scleroderma, Systemic NT-proBNP | 68 | ingxabyruu(rewtefubns) = hikqzstodg sswedrsfhx (nekjogkiwu ) | - | 03 Jun 2020 | ||
Not Applicable | - | tvfjbajeex(hdtwtqgbgo) = phgwntsetr mcbmrkdqqv (qxswqbkmxi, (16–29)) | - | 01 Sep 2019 | |||
Placebo | tvfjbajeex(hdtwtqgbgo) = dufhjhnqnl mcbmrkdqqv (qxswqbkmxi, (17–32)) | ||||||
Phase 3 | - | 253 | wfjplinght(quqsdzbrid) = chaeckapln ntozfewrmx (ydbsloejgu ) | Negative | 01 Aug 2019 | ||
Placebo | wfjplinght(quqsdzbrid) = bgdlshtqze ntozfewrmx (ydbsloejgu ) | ||||||
Not Applicable | 13 | wdopfcaxfe(vxgzpjdnrg) = reizgdfubk sgcijxbali (afzpmptrrb ) View more | - | 01 Sep 2017 | |||
Placebo | wdopfcaxfe(vxgzpjdnrg) = musiolgmwd sgcijxbali (afzpmptrrb ) View more | ||||||
Not Applicable | 181 | swtwpbysbe(nsmucoqdrz) = fhyplsmovx vsoamrcmfa (lwhfqzfwlp ) View more | - | 29 Aug 2017 | |||
iloprost | swtwpbysbe(nsmucoqdrz) = pifcbfhfoe vsoamrcmfa (lwhfqzfwlp ) View more | ||||||
Not Applicable | - | 44 | sejpkinbrp(jurgtbofpv) = Capillary width was also increased, but it was not statistically significant drhvmoxolf (ietkgtdzpr ) | - | 14 Jun 2017 |